文献速递特殊人群用药治疗药物监测与药物基因组学

半机制群体药代动力学模型预测妊娠及产后替诺福韦前药在血浆和细胞基质中的暴露

Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum.
PubMed 文献 · Clin Pharmacokinet · 2025-11-12

本研究开发半机制群体药代动力学模型,同时描述TDF和TAF衍生部分在妊娠及产后的药代动力学,并模拟比较两者暴露。模型显示妊娠中期和晚期TFV表观清除率增加,TAF生物利用度降低,但TAF在PBMC中仍维持约5倍于TDF的TFV-DP浓度。

要点

  • 妊娠中期和晚期TFV表观清除率分别增加24.9%和13.1%。
  • TAF生物利用度在妊娠中期和晚期分别降低17.3%和5.1%。
  • 妊娠期TAF在PBMC中TFV-DP浓度约为TDF的5倍。

核心结论

  • 半机制模型可描述TDF和TAF在妊娠及产后的药代动力学变化。
  • 妊娠期TAF在PBMC中维持高于TDF的TFV-DP暴露。

研究设计与样本

  • 开发半机制群体药代动力学模型,同时描述TDF和TAF衍生部分的药代动力学。
  • 进行临床试验模拟,比较妊娠与产后TDF和TAF的药代动力学。

主要发现

  • 血浆TAF和TFV分别用一室和二室模型描述,一级吸收。
  • TAF给药后血浆TFV消除较慢,模型纳入转运室。
  • PBMC和干血斑用生物相模型纳入。
  • TDF组妊娠中期和晚期TFV表观清除率分别增加24.9%和13.1%。
  • 产后TFV表观清除率较非妊娠女性低9.3%。

关键数值与推荐

  • TAF生物利用度在妊娠中期和晚期分别降低17.3%和5.1%。
  • 产后TAF生物利用度较非妊娠女性增加18%。
  • 妊娠中期和晚期TAF在PBMC中TFV-DP浓度约为TDF的5倍。

临床怎么用

  • 模型可支持妊娠期HIV治疗和预防的剂量策略优化研究。
  • 妊娠期TAF在PBMC中维持较高TFV-DP浓度,与TDF不同。

局限性

  • 模型基于模拟,需进一步临床验证。
  • 干血斑与PBMC差异机制尚未完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Tenofovir (TFV)-based regimens are backbones of both HIV treatment and pre-exposure prophylaxis during pregnancy. Multiple studies have shown up to one-third decreases in dried blood spot tenofovir-diphosphate concentrations during pregnancy among participants taking tenofovir disoproxil fumarate (TDF). Currently, there are no mechanism-based models describing the pharmacokinetics of tenofovir diphosphate (the active anabolite) in peripheral blood mononuclear cells (PBMCs) of pregnant individuals receiving TDF or tenofovir alafenamide (TAF), and the mechanisms behind observed differences between dried blood spots and PBMCs remain unclear. METHODS: To address this gap, we developed a semi-mechanistic model to simultaneously describe the pharmacokinetics of all clinically relevant TDF and TAF-derived moieties and conducted clinical trial simulations to compare TDF and TAF pharmacokinetics during pregnancy and postpartum. RESULTS: The pharmacokinetics of plasma TAF and TFV were best described by one-compartment and two-compartment models, respectively, with first-order absorption. A transit compartment was included to reflect the slower elimination rate of plasma TFV after receiving TAF. Cellular matrix PBMC and dried blood spots were included using a biophase model. For TDF, plasma TFV apparent clearance increased by 24.9% and 13.1% during the second and third trimesters of pregnancy, respectively, compared with non-pregnant populations. In the postpartum period, plasma TFV apparent clearance in pregnant women was 9.3% lower than in non-pregnant women. The bioavailability for TAF decreased by 17.3% and 5.1% during the second and third trimesters, respectively, and increased by 18% during the postpartum period relative to non-pregnant women. In pregnant women, simulations showed that TAF maintains approximately five times higher tenofovir diphosphate concentrations in PBMCs compared with TDF during the second and third trimesters, despite a decrease in PBMC tenofovir diphosphate concentrations for both drugs. This finding is consistent with the higher PBMC loading effect of TAF observed in non-pregnant populations. CONCLUSIONS: Our semi-mechanistic model provides a framework for understanding pregnancy-associated pharmacokinetic changes and supports future research to refine dosing strategies for HIV treatment and prevention in pregnancy.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Yu Y, Brooks KM, Doncel GF, et al. Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. Clin Pharmacokinet. 2025. PMID: 41222898. doi:10.1007/s40262-025-01589-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。